Hot Products
| Catalog No. | Information |
| CFN98711 | Brazilin Brazilin exhibits cancer preventive, anti-hepatotoxicity, antiplatelet activity, and anti-inflammatory activities, it also inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing of NF-κB activation in human dermal fibroblasts, thus, it might be used as a potential agent for treatment of UV-induced skin photoaging. Brazilin has anti-IKK activity, can selectively disrupt proximal IL-1 receptor signaling complex formation by targeting an IKK-upstream signaling components. Brazilin induces vasorelaxation by the increasing intracellular Ca(2+) concentration in endothelial cells of blood vessels and hence activating Ca(2+)/calmodulin-dependent NO synthesis. |
| CFN93653 | Brevifolincarboxylic acid Brevifolincarboxylic acid shows moderate antibacterial activity against Salmonella enteritidis , Salmonella typhimurium , and Salmonella abony, it (IC50 = 18.0 uM) also shows good antioxidant activity. Brevifolincarboxylic acid shows marked inhibitory effects on aryl hydrocarbon receptor -based bioassay activation by TCDD, and its effect is dose dependent. |
| CFN99694 | Brevilin A Brevilin A is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperactivated JAKs and STATs. Brevilin A shows antigiardial activity (IC50 = 16.1 μM) and is similarly active in vitro against Entamoeba histolytica (IC50 between 4.5 and 9 μM) and against Plasmodium falciparum (IC50 = 9.42 μM). |
| CFN90315 | Breviscapine Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1. Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue. Breviscapine can treat coronary disease, breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway . |
| CFN92601 | Britannilactone Britannilactone significantly reduces melanin production in a dose-dependent manner with the IC50 value of 15.5 uM. |
| CFN90220 | Britannin Britannin has strong cytotoxicity to HepG-2, MCF-7, MDBK and A-549 cells (IC50: 2.2, 5.9, 5.4, and 3.5 microg/mL, respectively). Britannin inhibits growth of MCF-7 and MDA-MB-468 breast cancer cells through the activation of the mitochondrial apoptotic pathway and may potentially serve as an agent for breast cancer therapy. |
| CFN92774 | Broussoflavonol B Broussoflavonol B is a potent growth inhibitor of ER-negative breast cancer stem-like cells, may be used to treat breast cancer. Broussoflavonol B increases the growth inhibitory activity of tamoxifen in tumorsphere cells derived from MCF7/TAM cells. |
| CFN97694 | Broussonin A Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin A shows estrogenic activity with ligand-binding activity of estrogen receptor, transcriptional activity of estrogen-responsive element-luciferase reporter genes. Broussonin A can significantly inhibit adipocyte differentiation in 3T3-L1 cells as measured fat accumulation using Oil Red O assay; it suppresses lipopolysaccharide (LPS)-stimulated inducible nitric oxide synthase (iNOS) expression at the transcriptional level through modulating NF-κB and down-regulation of the Akt and ERK signaling pathways. |
| CFN97695 | Broussonin B Broussonins A and B, new phytoalexins from diseased paper mulberry. Broussonin B can induce neurite outgrowth in PC-12 cells at concentration of 50 microg/ml, and show moderate inhibitory activities against a chymotrypsin-like activity of the proteasome.Broussonin B also can significantly inhibit adipocyte differentiation in 3T3-L1 cells as measured fat accumulation using Oil Red O assay. |
| CFN97474 | Broussonin E Broussonin E could suppress inflammation by modulating macrophages activation state via inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway, and can be further developed as a promising drug for the treatment of inflammation-related diseases such as atherosclerosis. |
